You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 2021284019
Dec 20214902
Jan 20228007
Feb 202268010
Mar 202220405
Apr 202282014
May 202266025
Jun 20222608
Jul 20222803
Aug 20225403
Sep 20223809
Oct 20222007
Nov 202244010
Dec 20222804
Jan 20232409
Feb 20232002
Mar 20232607
Apr 20232804
May 2023602
Jun 2023804
Jul 202322010
Aug 202326011
Sep 20231604
Oct 20233303
Nov 20232805
Dec 20232201
Jan 20242801
Feb 20243207
Mar 202432014
Apr 20241206
May 20242403
Jun 20241806
Jul 20241603
Aug 20242606
Total15180234